Breaking News
Get 40% Off 0
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March. Read full update
Close

Teva Pharma Industries Ltd ADR (TEVAy)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
14.90 -0.05    -0.33%
02:08:19 - Delayed Data. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  Germany
ISIN:  US8816242098 
S/N:  883035
  • Volume: 1,176
  • Bid/Ask: 14.85 / 14.90
  • Day's Range: 14.90 - 14.95
Teva ADR 14.90 -0.05 -0.33%

TEVAy Recent Sentiments

 
This page contains information on users’ sentiments for the Teva Pharma Industries Ltd ADR stock, which are displayed both on charts of different periods of time and on a detailed table.
Start Date Username Call Open Rate End Date Chg. %
Aug 02, 2023 רפי מנטין   8.58 Nov 30, 2023 @ 8.84 +3.03%
Apr 17, 2023 Michael Bleiberg   7.62 Apr 24, 2023 @ 7.58 -0.52%
Apr 14, 2023 ללו חורש   7.90 Apr 17, 2023 @ 7.70 -2.53%
Jan 18, 2023 Alex Teutsch   10.00 Feb 10, 2023 @ 9.60 -4.00%
Oct 06, 2022 Torolls RaRoyce   8.92 Oct 28, 2022 @ 8.96 +0.45%
Jul 18, 2022 Nir NR   6.94 Aug 13, 2022 @ 10.95 +57.78%
Jul 07, 2022 ללו חורש   7.42 Jul 11, 2022 @ 6.80 -8.36%
Apr 29, 2022 Ákos Varga   8.46 May 20, 2022 @ 8.02 -5.20%
Apr 06, 2022 Michael Bleiberg   9.02 Apr 11, 2022 @ 9.46 +4.88%
Mar 21, 2022 Michael Bleiberg   7.14 Mar 28, 2022 @ 7.77 +8.82%
Feb 09, 2022 Michael Peklo   7.82 Mar 04, 2022 @ 6.79 -13.17%
Feb 01, 2022 Michael Bleiberg   7.71 Feb 07, 2022 @ 7.55 -2.08%
Jan 24, 2022 Michael Bleiberg   7.35 Jan 31, 2022 @ 7.53 +2.45%
Jan 14, 2022 Michael Peklo   7.93 Feb 04, 2022 @ 7.47 -5.80%
Jan 13, 2022 Michael Bleiberg   7.97 Jan 17, 2022 @ 7.98 +0.13%
Jan 05, 2022 Michael Bleiberg   7.50 Jan 10, 2022 @ 8.04 +7.20%
Dec 28, 2021 Michael Bleiberg   7.74 Jan 03, 2022 @ 7.36 -4.91%
Dec 21, 2021 Michael Bleiberg   7.50 Dec 27, 2021 @ 7.48 -0.27%
Oct 12, 2021 Gilles DAZZAN   8.57 Nov 05, 2021 @ 7.86 -8.28%
Aug 04, 2021 Евгения Литвин   8.33 Aug 27, 2021 @ 7.99 -4.08%
Apr 27, 2021 Philipp Schütze   8.47 May 21, 2021 @ 9.10 +7.44%
Apr 26, 2021 Priska Hämmerli   8.83 May 21, 2021 @ 9.10 +3.06%
Apr 07, 2021 Mads Johansen   9.62 Apr 30, 2021 @ 8.92 -7.28%
Mar 12, 2021 Jorn Falk   9.19 Apr 02, 2021 @ 9.82 +6.86%
Mar 11, 2021 Marcus Lüttgen   9.47 Apr 02, 2021 @ 9.82 +3.70%
Mar 02, 2021 Benjamin Bedorf   8.90 Mar 12, 2021 @ 9.04 +1.57%
Feb 19, 2021 Sven Luther   9.02 Mar 12, 2021 @ 9.04 -0.22%
Feb 16, 2021 Thai Pitti   9.30 Mar 12, 2021 @ 9.04 -2.80%
Feb 10, 2021 chiara carreri   10.86 Mar 05, 2021 @ 8.77 -19.24%
Feb 08, 2021 Benjamin Bedorf   10.58 Feb 14, 2021 @ 9.19 -13.14%
Feb 04, 2021 Jorn Falk   10.32 Feb 26, 2021 @ 8.95 -13.28%
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

TEVA Comments

Write your thoughts about Teva Pharmaceutical Industries Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
TSahi Livnoni
TSahi Livnoni 18 hours ago
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Post er the average of the new price targets is 19$ Nice. This will continue all the way to 30, 40$.
TSahi Livnoni
TSahi Livnoni May 07, 2024 8:05AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
One day to ER of Q1
TSahi Livnoni
TSahi Livnoni May 07, 2024 8:05AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
New price target of 17$ by Barclays analyst
TSahi Livnoni
TSahi Livnoni Apr 11, 2024 8:56AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
TSahi Livnoni
TSahi Livnoni Apr 11, 2024 8:55AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China April 11, 2024 8:30 AM AJOVY confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month All critical efficacy endpoints met significance as set out apriori through hierarchical testing AJOVY confirmed a favorable safety profile
TSahi Livnoni
TSahi Livnoni Apr 11, 2024 8:55AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China April 11, 2024 8:30 AM AJOVY confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month All critical efficacy endpoints met significance as set out apriori through hierarchical testing AJOVY confirmed a favorable safety profile
TSahi Livnoni
TSahi Livnoni Mar 23, 2024 9:54PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
1% on a Friday with 9.13M volume someone is buying.
TSahi Livnoni
TSahi Livnoni Mar 13, 2024 10:16AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
simple story of debt reduction and value going up. revenue growth will set the pace will move up in the next 2-3 years to about 30-40$
ritchie lee
ritchie lee Jan 22, 2024 1:49PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
long trend starting
Ramba Łej
Kubizm Jan 22, 2024 1:49PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
hopefully ! Ive been w8ing for it for 3 y xD
Ramba Łej
Kubizm Sep 14, 2023 10:26AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
11,40 will hold as celling or convert to floor :)?
Ramba Łej
Kubizm Aug 02, 2023 8:06AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
looking good on pre-market. Wonder how USA downgrade might spoil the fun here
BumHunters Archer
JohnJenga Aug 02, 2023 8:06AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
25 next year seems quite doable
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email